Supplemental Figures to manuscript *"Evi1* counteracts anti-leukemic and stem cell inhibitory effects of *all-trans* retinoic acid on *Flt3*-ITD/*Npm1c*-driven acute myeloid leukemia cells" by Nguyen et al.



Figure S1. Proportion of GFP positive cells among LC^{*Flt3-ITD/Npm1c*} **transduced with empty vector (***Flt3-ITD/Npm1c_vec***) or with pMSCV_FLAG-***Evi1_IRES_GFP (Flt3-ITD/Npm1c_Evi1***). Representative flow cytometric analysis performed after sorting. SSC, side scatter. As negative control (Ctrl), a cell line established from primary murine AML cells (RN2) was used.**



Figure S2. Experimental expression of *Evi1* counteracts the anti-leukemic and stem cell inhibitory effects of atRA on *Flt3*-ITD/*Npm1c* driven murine AML cells. Bone marrow $LC^{Flt3-ITD/Npm1c_vec}$ and $LC^{Flt3-ITD/Npm1c_Evi1}$ were treated with the indicated concentrations of atRA or with solvent for 48 h (a), or with 1 μ M atRA or the corresponding amount of solvent for 72 h (b, c). (a) Apoptosis. Representative flow cytometric analysis of Annexin V stained cells. Annexin V negative and positive cells were considered as viable and apoptotic, respectively. (b) Myeloid differentiation. Representative flow cytometric analyses of Gr1⁺ cells among CD11b⁺ GFP⁺ cells. Pre-gating on the GFP positive population restricted the analysis to leukemic cells. Cut-offs for marker positivity were determined using isotype control antibodies. (c) Serial replating assay. Representative images of colonies from second plating. Scale bars, 2mm. Images were taken using TissueFAXS i PLUS (TissueGnostics, Vienna, Austria) and TissueFAXS v.4.2 software.